Advice
Following a full resubmission
Adefovir dipivoxil (Hepsera) is accepted for restricted use within NHS Scotland for the treatment of chronic hepatitis B in adults with either compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis, or decompensated liver disease. Its use is restricted to patients who demonstrate lamivudine resistance.
Download detailed advice58KB (PDF)
Medicine details
- Medicine name:
- Adefovir dipivoxil (Hepsera®)
- SMC ID:
- 54/03
- Indication:
Chronic hepatitis B
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 09 May 2005